Ann: New Clinical Practice Guidance Recommends Use of BIS, page-66

First 66 Last

Share
Profile

Follow
Aqua65

5,041 Posts.

3052

18/02/24

22:07

Post #: 72473647
Share

Originally posted by Twodogs196: ↑

Hi Mirri..

I can't add much to the AUD revenue model as I have never been told.. every time I mentioned it to the prior people I was brushed off shall we say .. all I know is that we are currently "giving it away " in Aus and other places outside US as they never focussed on those markets and never had any intention to for a long time ... was always US .. US ... and the US .. its on the list of things that need attention to and change... all I can say is I'm "pretty sure" its on an ongoing SAAS contract model but if you look at ( was it) the June 4c there were tables showing revenue breakdown from monthly contract charge .. ie $1,500 plus.. $1,000 - $1,500.. etc ( those figures quoted there were a memory stab.. ) .. the point being the table also showed revenue from outside US of which AUS is mostly all .. and total rev from outside US was 3% if lucky of total revenue.. and we now have 400 devices here in Aus.. as I said.. current AUS model until changed is giving it away..

I do know this has been brought up with PB and MG ( I did .. ) .. and all I can say atm is its a watch this space.. existing contracts need to unwind/finish and then go from there.. just another thing for the new mod to unwind and sort out ..

cheers ..

Expand

These clinics have Sozo machines —hopefully ImpediMed will also be very involved nationally in the US in the next month with Lymphedema awareness and education for best care & treatments , including prevention for post - cancer survivors & required monitoring for onset and management.

Sales with best technical & health management development support is clearly priority for targeted hospitals & centres.

https://youtube.com/shorts/VVNN9ZRFWzw?si=Rb4rE4yt_KH5McXO

Very good to subscribe to this therapists videos in Y0u Tube.

Last edited by Aqua65: 18/02/24

IPD Price at posting: 8.8¢ Sentiment: Buy Disclosure: Held
3 Upvote

1 Great analysis

Reply